03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
18:47 , Mar 17, 2017 |  BioCentury  |  Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19 -targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell...